The role of Genentech BioOncology
Over the past 20 years, Genentech scientists have made important contributions toward understanding apoptotic pathways and have identified several key genes that encode proteins associated with apoptosis.
Identification of a novel pro-apoptotic signaling molecule (Apo2 ligand)
- Using sequence information from human genome databases, Genentech researchers were among the first to identify a novel pro-apoptotic signaling molecule and infer the existence of a novel receptor molecule1
Identification of a novel decoy receptor for endogenous Apo2L/TRAIL
- DcR1 was identified as a novel receptor that appeared to act as an indirect inhibitor of apoptosis by sequestering the pro-apoptotic signaling molecule Apo2L/TRAIL2
Exploration and identification of additional receptor molecules involved in the regulation of apoptosis
- Building on previous work, Genentech researchers continued to extend the understanding of the multitude of proteins involved in maintaining the delicate balance between cell survival and death3,4
- These discoveries are paving the way for novel therapeutic approaches to the management of cancer, and Genentech BioOncology remains dedicated to the research and development of novel therapeutics that target different aspects of the apoptotic pathways